Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose benefits of therapy and may be predisposed to further resistance. Entecavir (ETV) resistance (ETVr) results from HBV reverse transcriptase substitutions at positions T184, S202, or M250, which emerge in the presence of lamivudine (LVD) resistance substitutions M204I/V ± L180M. Here, we summarize results from comprehensive resistance monitoring of patients with HBV who were continuously treated with ETV for up to 5 years. Monitoring included genotypic analysis of isolates from all patients at baseline and when HBV DNA was detectable by polymerase chain reaction (≥300 copies/mL) from Years 1 through 5. In addition, genotyping was performed on isolates from patients experiencing virologic breakthrough (≥1 log10 rise in HBV DNA). In vitro phenotypic ETV susceptibility was determined for virologic breakthrough isolates, and for HBV containing novel substitutions emerging during treatment. The results over 5 years of therapy showed that in nucleoside‐naïve patients, the cumulative probability of genotypic ETVr and genotypic ETVr associated with virologic breakthrough was 1.2% and 0.8%, respectively. In contrast, a reduced barrier to resistance was observed in LVD‐refractory patients, as the LVD resistance substitutions, a partial requirement for ETVr, preexist, resulting in a 5‐year cumulative probability of genotypic ETVr and genotypic ETVr associated with breakthrough of 51% and 43%, respectively. Importantly, only four patients who achieved <300 copies/mL HBV DNA subsequently developed ETVr. Conclusion: Long‐term monitoring showed low rates of resistance in nucleoside‐naïve patients during 5 years of ETV therapy, corresponding with potent viral suppression and a high genetic barrier to resistance. These findings support ETV as a primary therapy that enables prolonged treatment with potent viral suppression and minimal resistance. (HEPATOLOGY 2009.)

[1]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[2]  A. Cross,et al.  Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. , 2006, Gastroenterology.

[3]  A. Cross,et al.  Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive adults: 24 wk results (EARLY study) , 2006 .

[4]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[5]  J. Marrero,et al.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. , 2005, Journal of hepatology.

[6]  D. Snydman.  A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B , 2007 .

[7]  A. Bisceglie,et al.  Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine , 2006 .

[8]  M. Buti,et al.  Antiviral‐resistant hepatitis B virus: can we prevent this monster from growing? , 2007, Journal of viral hepatitis.

[9]  F. Zoulim,et al.  In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants , 2007, Antimicrobial Agents and Chemotherapy.

[10]  Colin W Shepard,et al.  Hepatitis B virus infection: epidemiology and vaccination. , 2006, Epidemiologic reviews.

[11]  Huiling Yang,et al.  Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV , 2005, Antiviral therapy.

[12]  A. Cross,et al.  [781] FOUR YEAR ASSESSMENT OF ETV RESISTANCE IN NUCLEOSIDE-NAIVE AND LAMIVUDINE REFRACTORY PATIENTS , 2007 .

[13]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  E. Schiff,et al.  A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. , 2005, Gastroenterology.

[15]  Jean-Michel Pawlotsky,et al.  Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. , 2008, Gastroenterology.

[16]  C. Mazzucco,et al.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.

[17]  C. Mazzucco,et al.  Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.

[18]  J. Villeneuve,et al.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir , 2005, Hepatology.

[19]  Yoshiyuki Suzuki,et al.  Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[21]  Y. Liu,et al.  Evolution of multi‐drug resistant hepatitis B virus during sequential therapy , 2006, Hepatology.

[22]  Huiling Yang,et al.  In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents , 2006, Antiviral therapy.

[23]  J. Villeneuve,et al.  Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. , 2007, Journal of hepatology.

[24]  M. Manns,et al.  In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. , 2001, Antimicrobial agents and chemotherapy.

[25]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[26]  R. Colonno,et al.  Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. , 2008, Journal of hepatology.

[27]  C. Mazzucco,et al.  Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance , 2008, Hepatology.

[28]  F. Zoulim,et al.  Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. , 2008, Journal of hepatology.

[29]  W. Delaney.  Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. , 2007, The Journal of antimicrobial chemotherapy.

[30]  S. Yu,et al.  Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil , 2006, Gut.

[31]  S. Sarafianos,et al.  Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC) , 2001, Journal of Virology.

[32]  C. Chapron,et al.  514 HBV resistance determination from the telbivudine globe registration trial , 2006 .

[33]  D. Richman.  The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B , 2000, Hepatology.

[34]  M. Manns,et al.  In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil , 2001, Antimicrobial Agents and Chemotherapy.

[35]  M. Imamura,et al.  Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif , 2006, Antimicrobial Agents and Chemotherapy.

[36]  Ronald E. Rose,et al.  Inhibition of Hepatitis B Virus Polymerase by Entecavir , 2007, Journal of Virology.

[37]  H. Lee,et al.  Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy , 2006, Hepatology.